Personalized 177Lu-octreotate peptide receptor radionuclide therapy of neuroendocrine tumours: a simulation study

被引：0
作者：
Michela Del Prete
François-Alexandre Buteau
Jean-Mathieu Beauregard
机构：
[1] Université Laval,Department of Radiology and Nuclear Medicine, and Cancer Research Center
[2] CHU de Québec – Université Laval,Department of Medical Imaging, and Oncology Branch of Research Center
来源：
European Journal of Nuclear Medicine and Molecular Imaging | 2017年 / 44卷
关键词：
Personalized; Peptide receptor radionuclide therapy; Lu-octreotate; Dosimetry; Neuroendocrine tumours;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：1490 / 1500
页数：10
相关论文
共 50 条
[41]   The efficacy of 177Lu-DOTATATE peptide receptor radionuclide therapy (PRRT) in patients with metastatic neuroendocrine tumours: a systematic review and meta-analysis [J].
Zhang, Jie ;
Song, Qi ;
Cai, Liang ;
Xie, Ying ;
Chen, Yue .
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2020, 146 (06) :1533-1543
[42]   The efficacy of 177Lu-DOTATATE peptide receptor radionuclide therapy (PRRT) in patients with metastatic neuroendocrine tumours: a systematic review and meta-analysis [J].
Jie Zhang ;
Qi Song ;
Liang Cai ;
Ying Xie ;
Yue Chen .
Journal of Cancer Research and Clinical Oncology, 2020, 146 :1533-1543
[43]   Metastatic or locally advanced mediastinal neuroendocrine tumours: outcome with 177Lu-DOTATATE-based peptide receptor radionuclide therapy and assessment of prognostic factors [J].
Adnan, Aadil ;
Kudachi, Shreyas ;
Ramesh, Sudha ;
Prabhash, Kumar ;
Basu, Sandip .
NUCLEAR MEDICINE COMMUNICATIONS, 2019, 40 (09) :947-957
[44]   Peptide receptor radionuclide therapy with 177Lu-DOTATATE: the IEO phase I-II study [J].
Lisa Bodei ;
Marta Cremonesi ;
Chiara M. Grana ;
Nicola Fazio ;
Simona Iodice ;
Silvia M. Baio ;
Mirco Bartolomei ;
Dario Lombardo ;
Mahila E. Ferrari ;
Maddalena Sansovini ;
Marco Chinol ;
Giovanni Paganelli .
European Journal of Nuclear Medicine and Molecular Imaging, 2011, 38 :2125-2135
[45]   Single centre retrospective review of outcome of 177Lu-DOTATATE peptide receptor radionuclide therapy in the treatment of progressive metastatic neuroendocrine tumours: Survival, toxicity, and prognostic factors [J].
Alsadik, Shahad ;
Gnanasegaran, Gopinath ;
Chen, Luohai ;
Quigley, Ann-Marie ;
Mandair, Dalvinder ;
Toumpanakis, Christos ;
Caplin, Martyn ;
Navalkissoor, Shaunak .
JOURNAL OF NEUROENDOCRINOLOGY, 2022, 34 (11)
[46]   Pituitary function following peptide receptor radionuclide therapy for neuroendocrine tumours [J].
Elston, Marianne S. ;
Love, Amanda ;
Kevat, Dev ;
Carroll, Richard ;
Siow, Zhen Rong ;
Pattison, Sharon ;
Boyle, Veronica ;
Segelov, Eva ;
Strickland, Andrew H. ;
Wyld, David ;
Gauci, Richard ;
Kennedy, Kim ;
Ransom, David .
CANCER MEDICINE, 2021, 10 (23) :8405-8411
[47]   Long-Term Outcomes of Submaximal Activities of Peptide Receptor Radionuclide Therapy with 177Lu-DOTATATE in Neuroendocrine Tumor Patients [J].
Minczeles, Noemie S. ;
de Herder, Wouter W. ;
Feelders, Richard A. ;
Verburg, Frederik A. ;
Hofland, Johannes ;
Brabander, Tessa .
JOURNAL OF NUCLEAR MEDICINE, 2023, 64 (01) :40-46
[48]   Minor changes in effective half-life during fractionated 177Lu-Octreotate therapy [J].
Garske, Ulrike ;
Sandstrom, Mattias ;
Johansson, Silvia ;
Sundin, Anders ;
Granberg, Dan ;
Eriksson, Barbro ;
Lundqvist, Hans .
ACTA ONCOLOGICA, 2012, 51 (01) :86-96
[49]   Safety of Peptide Receptor Radionuclide Therapy with 177Lu-DOTATATE in Neuroendocrine Tumor Patients with Chronic Kidney Disease [J].
Alsadik, Shahad ;
Gnanasegaran, Gopinath ;
Chen, Luohai ;
Mandair, Dalvinder ;
Toumpanakis, Christos ;
Caplin, Martyn ;
Navalkissoor, Shaunak .
JOURNAL OF NUCLEAR MEDICINE, 2022, 63 (10) :1503-1508
[50]   A Care Process Model to Deliver 177Lu-Dotatate Peptide Receptor Radionuclide Therapy for Patients With Neuroendocrine Tumors [J].
Kasi, Pashtoon Murtaza ;
Maige, Catherine L. ;
Shahjehan, Faisal ;
Rodgers, Jessica M. ;
Aloszka, Debora L. ;
Ritter, Ashton ;
Andrus, Margaret L. ;
Mcmillan, Jessica M. ;
Mody, Kabir ;
Sharma, Akash ;
Jain, Manoj K. .
FRONTIERS IN ONCOLOGY, 2019, 8
12345